Sunday, July 22, 2018
 
 
Company News: Page (1) of 1 - 07/03/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Intravenous (IV) Iron Drugs 2018: Global Strategic Business Outlook to 2024 - Expanding Pool of ESRD and CKD Patients: The Major Growth Driver

(July 03, 2018)

Dublin, July 03, 2018 (GLOBE NEWSWIRE) -- The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand.


The report profiles 21 companies including many key and niche players such as:

  • Allergan Plc. (Ireland)
  • AMAG Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo, Inc. (USA)
  • Luitpold Pharmaceuticals, Inc. (USA)
  • American Regent, Inc. (USA)
  • Pharmacosmos A/S (Denmark)
  • Sanofi US (USA)
  • Vifor Pharma Ltd. (Switzerland)
  • Vifor Fresenius Medical Care Renal Pharma (Switzerland)

Key Topics Covered

1. GLOBAL MARKET OVERVIEW
Iron Deficiency Anemia (IDA)
An Overview
Intravenous (IV) Iron Drugs Market
A Quick Primer
US and Europe Dominate IV Iron Market
Asia-Pacific
The Fastest Growing Market
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
Ferinject/Injectafer
The Leading Intravenous Iron Drug Globally
Venofer®
Looses Ground to Ferinject
Feraheme Obtains Broader Label Approval
Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA
Gluconate (Ferrlecit® and Nulecit)
Dextran
Global Market Leaders

2. GROWTH DRIVERS & MARKET TRENDS
Expanding Pool of ESRD and CKD Patients
The Major Growth Driver for Intravenous (IV) Iron Drugs
ESRD Prevalence Statistics: An Opportunity Indicator
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
Dialysis Patients
A Major Market for Intravenous Iron Supplements
Ageing Population Drives Demand for IV Iron Drugs
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure
A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Correction of IDA in Pregnancy Signals Opportunities
Women’s Health
A Key Growth Opportunity
Perioperative and Postoperative Anemia
A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

3. REGULATORY OVERVIEW
Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada

4. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS

5. RECENT INDUSTRY ACTIVITY
AMAG to Expand Feraheme® Label
Pharmacosmos and Laboratoire Aguettant to Commercialize Monover® in France
Pharmacosmos and Pfizer to Commercialize Monover® in Brazil
Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV) Administration
Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer® in Japan
Lupin Announces the Launch of Novel Injectable Iron Formulation in India
Pharmacosmos and Pfizer to Commercialize Monofer® in Canada

6. FOCUS ON SELECT PLAYERS
Allergan Plc. (Ireland)
AMAG Pharmaceuticals, Inc. (USA)
Daiichi Sankyo, Inc. (USA)
Luitpold Pharmaceuticals, Inc. (USA)
American Regent, Inc. (USA)
Pharmacosmos A/S (Denmark)
Sanofi US (USA)
Vifor Pharma Ltd. (Switzerland)
Vifor Fresenius Medical Care Renal Pharma (Switzerland)

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 21 (including Divisions/Subsidiaries 22)

The United States ((5)
Japan (2)
Europe (7)
- France (1)
- Germany (1)
- The United Kingdom (1)
- Rest of Europe (4)
Asia-Pacific (Excluding Japan) (8)

For more information about this report visit https://www.researchandmarkets.com/research/b9925f/intravenous_iv?w=12

CONTACT: CONTACT: ResearchAndMarkets.com         Laura Wood, Senior Manager         [email protected]         For E.S.T Office Hours Call 1-917-300-0470         For U.S./CAN Toll Free Call 1-800-526-8630         For GMT Office Hours Call +353-1-416-8900         Related Topics: Infusions and Injectables , Hematological Drugs 

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines